Feasibility and Efficacy of Lorlatinib in Japanese Patients With Relapsed/Refractory ALK ‐Aberrant Neuroblastoma
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70511 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Takashi Imazu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Neuroblastoma, Anaplastic Lymphoma Kinase, Lactams, Macrocyclic, Neoplasm Recurrence, Local. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Lorlatinib, a third‐generation ALK inhibitor, was administered off‐label to five heavily pretreated patients with relapsed or refractory ALK ‐aberrant neuroblastoma. ALK alterations included F1174L, R1275Q, BEND5 :: ALK fusion, and ALK amplification; three patients had MYCN amplification. Best responses were three partial responses and two disease progressions. The longest progression‐free survival (6.7 months) occurred in a patient with F1174L and non‐amplified MYCN , whereas rapid progression was observed in two MYCN ‐amplified cases. Lorlatinib was generally well tolerated with manageable adverse events. These findings suggest that lorlatinib is a feasible therapeutic option in ALK ‐aberrant neuroblastoma and that clinical heterogeneity in treatment response warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
- Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Department of Pediatrics, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Pediatrics, University of Fukui, Fukui, Japan.
ORCID-Profile: Takashi Imazu, Hirohito Kubota, Satoshi Saida, Shuro Nishio, Yoshinori Uchihara, Yusuke Imanaka, Kimiyoshi Sakaguchi, Itaru Kato, Yoshiyuki Takahashi, Katsutsugu Umeda
Zitieren
APA
Imazu, T., Kubota, H., Saida, S., Nishio, S., Tojo, R., Uchihara, Y., Akazawa, R., Kouzuki, K., Imanaka, Y., Sakaguchi, K., Irie, M., Kato, I., Takahashi, Y., Umeda, K., & Takita, J. (2026). Feasibility and Efficacy of Lorlatinib in Japanese Patients With Relapsed/Refractory ALK ‐Aberrant Neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70511
Vancouver
Imazu T, Kubota H, Saida S, Nishio S, Tojo R, Uchihara Y, et al. Feasibility and Efficacy of Lorlatinib in Japanese Patients With Relapsed/Refractory ALK ‐Aberrant Neuroblastoma. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70511
BibTeX
@article{Imazu2026,
author = {Imazu, Takashi and Kubota, Hirohito and Saida, Satoshi and Nishio, Shuro and Tojo, Ryunosuke and Uchihara, Yoshinori and Akazawa, Ryo and Kouzuki, Kagehiro and Imanaka, Yusuke and Sakaguchi, Kimiyoshi and Irie, Masahiro and Kato, Itaru and Takahashi, Yoshiyuki and Umeda, Katsutsugu and Takita, Junko},
title = {Feasibility and Efficacy of Lorlatinib in Japanese Patients With Relapsed/Refractory ALK ‐Aberrant Neuroblastoma},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70511}
}
EUVIMED